GAMMA Investing LLC Purchases 41,767 Shares of Omnicell, Inc. (NASDAQ:OMCL)

GAMMA Investing LLC boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 2,892.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,211 shares of the company's stock after buying an additional 41,767 shares during the quarter. GAMMA Investing LLC owned 0.09% of Omnicell worth $1,511,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of OMCL. Smartleaf Asset Management LLC boosted its stake in shares of Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after purchasing an additional 273 shares during the period. Johnson Financial Group Inc. purchased a new stake in shares of Omnicell during the fourth quarter valued at $37,000. Van ECK Associates Corp boosted its stake in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Omnicell during the fourth quarter valued at $53,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after purchasing an additional 355 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OMCL has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their target price on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Wells Fargo & Company reissued an "overweight" rating and set a $37.00 target price (up from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Bank of America boosted their target price on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Finally, Benchmark lowered their target price on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.83.

Omnicell Stock Down 0.8%

Shares of OMCL stock traded down $0.22 on Wednesday, hitting $28.27. The stock had a trading volume of 489,057 shares, compared to its average volume of 575,208. The company has a quick ratio of 1.23, a current ratio of 1.38 and a debt-to-equity ratio of 0.13. The business has a 50 day moving average price of $29.57 and a 200 day moving average price of $36.69. The company has a market cap of $1.32 billion, a PE ratio of 61.46 and a beta of 0.78. Omnicell, Inc. has a one year low of $22.66 and a one year high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. The firm had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The firm's quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.03 earnings per share. Research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.